Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, 1795:TT) is pleased to announce that the Company is recognized by Corporate Livewire as the 2017 winner of the “Pharmaceutical Research Company of The Year” of its “Healthcare and Life Sciences Award”. The Corporate Livewire Awards program celebrates the business achievements of the global healthcare and life sciences community. Winners are chosen by the judging panel composed of over 100,000 corporate professionals.
Lotus Chairman Andrew Lin said, “Winning this award is a remarkable achievement for our team as this is the first global award for us. It highlights Lotus’ commitment to providing affordable healthcare around the world and our high and consistent standard of quality and service. We would like to thank our staffs for all their efforts, and our customers and business partners for their support.”
Lotus became an Alvogen company in 2014 and has thus repositioned itself to be the R&D and manufacturing hub for the group, focusing on cytotoxic, hormonal formulations and special dosage form. The Company also forms branded strategic partnerships to explore in-license or exclusive marketing opportunities for the unmet medical needs in key Asian countries. Lotus aims to grow both organically and through portfolio acquisitions. In 2017, the Company officially entered initial growth phase and has filed several oncology drug submissions, including Methotrexate, Gefitinib, Lenalidomide, and Vinorelbine, for the US and European markets.